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- Besides UV-induced DNA damage, UV-induced immunosuppression and inflammation are 
also essential in the development of actinic keratosis. 
- PDT does not only destroy tumor via direct cell destruction and indirectly via vascular 
shutdown but induce acute local inflammatory response and activates the innate and 
adaptive immune system. 
- Defective immune response to dysplastic keratinocytes may be the target of photodynamic 





5-ALA 5 aminolevulinic acid 
AK actinic keratosis 
APC antigen presenting cell 
CHS contact hypersensitivity 
CRT calreticulin 
cSCC cutaneous squamous cell cancer 
DAMP damage-associated molecular pattern 
DC dendritic cell 
HMGB1 high-mobility group box 1 protein 
HPV human papilloma virus 
HSP heat shock protein 










IEC intraepithelial carcinoma 
IL interleukin 
LC Langerhans cell 
MAC membrane attack complex 
MAL methylaminolevulinic acid 
MC mast cell 
MHC major histocompatibility complex 
MMP matrix metalloproteinase 
NK cell natural killer cell 
UV ultraviolet 
PAF platelet-activating factor 
PGE2 prostaglandin E2 
ROS reactive oxygen species 
SCC squamous cell carcinoma 
TGF-β transforming growth factor β 
TLR Toll-like receptor 
TNF-α tumor necrosis factor α  
Tregs regulatory T cells 
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The use of photodynamic therapy is extensive, due to its antitumoral, antibacterial and 
photorejuvenation effects. It destroys tumor via direct cell destruction and indirectly via 
vascular shutdown, induction of acute local inflammatory response and activation of the 
immune system. Both innate and adaptive immune cells are involved in the immunological 
effects of photodynamic therapy. In addition to UV-induced DNA damage, inflammation and 
immunosuppression are also essential elements in the pathogenesis of actinic keratosis. Both 
immunosuppression induced by UV and defective immune response to dysplastic keratinocytes 
may be the target of photodynamic therapy to eliminate actinic keratosis. These elements are 
discussed in the present review, highlighting the possible mechanism of photodynamic therapy 











Chronic UV exposure has a central role in the pathogenesis of cutaneous squamous cell cancer 
(cSCC) and its premalignant stage actinic keratosis (AK), through a multi-stage carcinogenesis 
process. In response to UV exposure, the tumor suppressor gene p53 is expressed and activated 
in the epidermis to induce cell cycle arrest and activate DNA repair machinery. The mutation 
of p53 is an early step in tumorigenesis, and characteristic of AK. Further mutations in 
oncogenes and immunosuppressive genes lead to the development of intraepidermal cancer 
(IEC) and finally to cSCC. The presence of multiple AK in one region reflects field 
cancerization, which means that surrounding keratinocytes contain also a certain amount of 
DNA damage.  1, 2, 3 In addition to UV-induced DNA damage, UV-induced inflammation and 
immunosuppression have major importance in the pathogenesis of AK and cSCC. 1, 2 When 
UV-induced keratinocyte skin cancer is transplanted into immunocompetent mouse, the tumor 
regresses, but if the recipient mouse is exposed to UV before transplantation, the tumor survives 
and grows. 4 The decreased immune surveillance and tumor growth are due to an impaired 
antigen presentation (altered morphology of antigen presenting cells (APCs)) and decreased 
expression of MHC class II, CD40, CD80, CD86 on their surface) and activation of regulatory 
T cells (Tregs), which are caused by UV-induced immunosuppressive soluble mediators (pl. 
IL-4, IL-10, TNF-α, PGE2), reactive oxygen species (ROS),  platelet-activating factor (PAF) 
secretion, isomerization of trans-urocanic acid to the immunosuppressive cis-urocanic acid, 
Toll-like receptor (TLR) 3 and TLR4 activation. 5,6. Nevertheless, incidence of AK in 
immunosuppressed patients is highly increased compared to immunocompetent individuals 
suggesting that functional immune surveillance is important in the clearance of pre-malignant 
skin lesions.6  
The mechanism of action of photodynamic therapy (PDT) is based on the production of ROS, 
vascular shut down and inflammatory, immunological processes.7 These immunological 
changes can boost anticancer processes but can be immunosuppressive as well.8 PDT eventuate 
a fast-therapeutic effect with excellent cosmetic outcome. However, there is great individual 
difference in the duration of response after PDT, the reasons for which are unclear.9 Although 
there may be individual differences in the cytotoxic effect (e.g. due to differences in 
photosensitizer uptake and conversion to PPIX, depth of cells), the induced immune response 
is likely to contribute to the variation in efficacy. The outcome of PDT, such as therapy 
resistance, early relapse or long-term remission, is presumably influenced by the relationship 
between the PDT-induced innate and adaptive immune response and the induced inflammation 
and immunosuppression in the microenvironment of the lesion. This review intends to address 
these processes and points out the unexplored issues of this field. 
Because squamous cell cancers arise via a neoplastic progression (AK to IEC to SCC), the goal 
of many studies is to analyze immunological events in each of these stages and compare them 
to each other. In this review, we summarize the reported data in each of these clinical entities, 















The current knowledge on immune profile of actinic keratosis and squamous cell cancer 
The contribution of chronic inflammation to the development of AK and cSCC was mainly 
investigated on HPV16 mice models. 10, 11, 12, 13, 14, 15 
There are only a few human studies which analyzed the immune cell composition of these 
lesions. 16, 17, 18, 19 Some of them compared the immune profiles in AK and cSCC to the immune 
infiltrate in photodamaged skin and/or IEC.17, 18, 19 The major results are summarized in Table 
1. 
INNATE IMMUNE CELLS 
Langerhans cells and dendritic cells 
CD1a+ Langerhans cells (LCs) are located in the epidermis, while CD11c+ conventional 
dendritic cells (cDCs) and plasmacytoid DCs are mainly in the dermis. DCs are the link between 
innate and adaptive immune response. They present antigens via MHC class I and class II 
complexes.20 
Immunohistochemical studies revealed that the presence of LC decreases gradually with 
malignant transformation.17 Furthermore, fewer CD11c+ HLA-DR+ cDCs are present in IEC 
and cSCC than in photodamaged skin.19 It might reflect the migration of cDCs from the lesion 
to the draining lymph node to present tumor associated antigens there.19 However, it was not 
confirmed yet with specific investigations. Moreover, Jang found significantly lower number 
of cDCs in AKs compared to IECs and cSCCs18, which contradicts to the previous results. In 
addition, BDCA-2+ HLA-DR+ plasmacytoid DCs were found to be more abundant in cSCCs 
compared to photodamaged skin or IEC. 19  
 
NK cells and macrophages 
 
Only one study analyzed the presence of CD3-CD56+ NK cells, and it has found a higher 
number of NK cells in photodamaged skin compared to IEC and cSCC. 19 
In contrast, the presence of CD68+ macrophages was more abundant in cSCCs compared to 
AKs.16, 17   
 
Neutrophils and mast cells 
 
Both neutrophils and mast cells could be detected in AKs, however, the presence of neutrophils 
was prominent in dysplastic and carcinoma tissues both in the center and in the border, while 
mast cells (MCs) were barely seen, in the tumor center. 10 A recent study, using MC-deficient/ 
HPV16 mice model, has found that the absence of MCs does not prevent the development of 
cSCC and does not alter the immune cell composition in cSCC.11 In contrast, previous 
publications reported decreased neoplastic progression in MC-deficient/ HPV16 mice, which 
was attributed to weaker activation of angiogenic factors and decreased ability of keratinocytes 
to reach hyperproliferative status.12 Furthermore, it has been demonstrated that chronic UV 
exposure significantly increases the number of MCs in the dermis and the immunosuppressive 
effect of MCs can promote skin tumor development.13 The degree of UV-induced 
immunosuppression and cSCC prevalence was significantly lower in MC-deficient mice or 









Considering the contradictory data, the role of MCs in the development of AK needs to be 
clarified in the future. 
 
ADAPTIVE IMMUNE CELLS 
 
B cells  
It was revealed, that the knock-out of complete adaptive immune system in HPV16 mice leads 
to the failure of initiation of chronic inflammation in premalignant conditions that results in 
decreased progression into cancer.15 When B lymphocytes were transferred to adaptive 
immune-deficient HPV16 mice, chronic inflammation along with the signs of premalignant 
transformation could be observed. 15 It suggests the important role of B lymphocytes in the 
onset of chronic inflammation and premalignant progression. CD20+ B cells are components 





Depending on the local cytokine milieu, which is determined by the APCs, the naïve T cells 
polarize into effector helper (Th) or cytotoxic T cells, to memory T cells, or to Tregs. 21 IL-12 
secreted by APCs promote the differentiation to Th1 cells. Th1 cells secrete IFN-γ, which 
contributes to the activation of macrophages, supports activity of NK cells and increase the 
expression of MHC I and MHC II on APCs and on normal cells. These cells also secrete TNF-
α, TNF-β, IL-2 and GM-CSF, which contribute to inflammation via macrophage, DC and 
complement activation and promote the proliferation of B cells. Th1 cells also play a major role 
in the activation and proliferation of CD8+ T cells 22, but it is also supported by IL-17, which is 
produced by Th17 cells. 23 Th17 cells release IL-17, which promotes the stimulation and 
generation of neutrophils, but the role of Th17 cells in tumors is ambiguous: depending on the 
microenvironment, they can act against the cancer or can stimulate tumor progression. 24 The 
presence of low concentrations of transforming growth factor-β (TGF-β) in the 
microenvironment leads to Th17 polarization, while the presence of high concentrations of 
TGF-β results in Treg polarization. 25 There are two types of regulatory T cells: natural Tregs 
and induced Tregs (iTregs). Natural Tregs develop in the thymus from CD4+ FoxP3+ T cells, 
while iTregs differentiate de novo at the periphery from CD4+ CD25+ T cells. 26, 27 Tregs and 
iTregs have distinct functions, natural Tregs recognize self-antigens, therefore they are 
important for protection against autoimmunity, while iTregs protect against excessive immune 
activation in response to non-self-antigens. 26 The proliferation of CD4+CD25+ Tregs is 
promoted by IL-10 and TGF-β. 28, 29 Tregs suppress the function of effector T cells via various 
mechanisms 30, and it has been shown that their number is increased in tumor tissues 29, even 
in IEC and in cSCC. 18 They possess immunosuppressive potential by the secretion of IL-10 
and TGF-β, leading to the inhibition of CD4+ T cell and dendritic cell activation and cytokine 
production, respectively. 18 
In human studies CD3+ T cells were found to be present more abundantly in AKs and IEC than 
in cSCC. 16, 19 Furthermore, high CD4+/CD8+ T cell ratio could be detected in cSCCs, 
suggesting that CD4+/CD8+ ratio might be a diagnostic indicator for progression into cSCC.19 
In another study, however, the presence of cytotoxic T cells was more abundant in cSCCs than 










There was no significant difference in the percentages of FoxP3+ Tregs and γδ T-cells in the 
photodamaged skin, IEC and cSCC samples. 19 It contradicts the results of Jang, who found 
higher proportion of FoxP3+Tregs in cSCCs than in AKs or IECs.18 Therefore, the role of 
Tregs should be also clarified in the future. 
 
Overall, there are only a few studies that analyzed the immune infiltrate of AKs, and these have 
revealed signs of both immune activation and immunosuppression. Immunosuppressive 
mechanisms can prevent the elimination of premalignant cells and initiate the development of 
AK and its progression into IEC and finally to cSCC. PDT can destroy directly the premalignant 
cells and, as we assume, break through the immunosuppression by inducing immune response 
to the destroyed cells.31  
However, more human studies focusing on the contradictory data (e.g. Langerhans cell, mast 
cell, regulatory T cell) should be performed, to find the answer to the question, is there an 
immune marker which could indicate treatment efficacy and the optimal therapy to certain 
patients? 
Immunological effects of photodynamic therapy 
Photodynamic therapy (PDT) is an effective anticancer treatment modality, which has a long-
standing history and a widespread field of application. Basically, three components are needed 
for PDT: oxygen, photosensitizer and proper wavelength of light. Cells (primarily the rapidly 
proliferating ones, but tumor stroma cells as well) accumulate the photosensitizer in subcellular 
organelles, which is then excited by light, resulting in the release of ROS, oxidizing 
biomolecules, which leads to tissue destruction and elimination of the damaged tissue by 
apoptosis, necrosis or autophagy. 32, 33, 34 As an indirect effect, PDT induces vascular shutdown 
by destroying endothelial cells and the vascular basement membrane, resulting in oxygen 
deprivation. Moreover, acute local inflammatory and immunological reactions, involving the 
innate and adaptive immune system, are induced, which contribute not only to control the 
growth of the primary tumor but also to prevent the development of a second one. 34, 35 
Nevertheless, there are studies suggesting the immunosuppressive effects of ALA-PDT as 
well.36, 37, 38 Hayami et al. used a murine contact hypersensitivity model.36 When trying to 
induce contact sensitization on previously PDT treated sites, the contact hypersensitivity was 
suppressed, even on the distant non-PDT treated skin as well.36 Matthews et al. reported human 
data on the immunosuppressive effect of PDT. They found that both 5-ALA and MAL-PDT 
could suppress positive Mantoux reaction on healthy volunteers, but only in the treated area.37 
Other experiments showed that platelet-activating factor (PAF) and other PAF-receptor ligands 
are generated locally after PDT, which cause systemic immunosuppression.38 Dose 
responsiveness of PDT-induced immunosuppression was confirmed in human skin. MAL-PDT 
at low fluence rate did not lead to immunosuppression, which was evaluated on Mantoux 
reactions.39 
      
Photosensitizers and DAMPs 
There are several types (porphyrins, porphyrin precursors, phthalocyanines, porphycenes, 
chlorines, pheophorbides, and others like methylene blue, rose Bengal, hypericin) of 
photosensitizers, which are applied not only for antitumoral but also for antibacterial purposes. 










Golgi apparatus, endoplasmic reticulum) and can be administered intravenously, orally or 
locally. Therefore, PDT is widely used in medicine and is being the subject of extensive 
research. 32, 40 5-aminolevulinic acid (5-ALA) and methylaminolevulinic acid (MAL) have 
approval in dermatological indications, including actinic keratosis. These two photosensitizers 
are accumulated in the cytoplasm and mitochondria as well. 41 After illumination with blue, red 
or sunlight, ROS are generated, which are highly cytotoxic and lead to cell damage. 42 Damage-
associated molecular patterns (DAMPs) are released from dying and injured cells, initiating 
immune response and antitumor immunity. 43 Calreticulin (CRT), heat shock protein (HSP) 70, 
HSP90, ATP and high-mobility group box 1 protein (HMGB1) are reported to be mainly 
involved in PDT associated immune response generation, depending on the type of 
photosensitizer. 7, 42 ALA-PDT can induce the expression of CRT, HSP70 and HMGB1, which 
were detected in a murine SCC model. 44 Among DAMPs, CRT and HMGB1 are thought to be 
associated with PDT-induced immunogenic cell death (ICD), while HSPs seem to be associated 
with PDT-induced apoptosis and ICD as well. 45, 46  
CRT, when appears on the cell surface, serves as a signal for DCs and macrophages to 
phagocyte the damaged cell and after ingestion the expression of tumor-antigens on APCs along 
with costimulatory molecules lead to the activation of T-cells. 47  
HSPs, associated with cell membrane not only activate DCs and NK cells but stimulate them 
to produce pro-inflammatory cytokines (TNF, IL-1β, IL-12, IL-6) and facilitate the presentation 
of tumor antigens. 45, 48, 49, 50, 51, 52 Extracellular HSPs form complexes with tumor-antigens and 
these complexes are taken up by APCs, initiating adaptive immune response. 48, 53 Moreover, 
HSPs can stimulate the migration and maturation of DCs by the upregulation of the expression 
of MHC class II, CD80, CD86, CD83, and CD40 costimulatory molecules. 54, 48  
HMGB1 protein regulates the transcription of p53 and nuclear factor-κB (NF-κB). 55 
Nevertheless, cell death accompanied by HMGB1 release is a form of ICD and is associated 
with the production of pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-8) by innate immune 
cells (neutrophils, monocytes and macrophages) which attracts naïve T cells, DCs and 
monocytes to the site of damage. 56, 57 The major events induced by PDT are summarized on 
Figure 1.  
Furthermore, extracellular nucleic acids, dsDNA, dsRNA can also act as DAMPs, but are 
released in later stages of cell death. 58 They bind to TLR7/8 and TLR9, and activate innate 
immune cells, including neutrophils and dendritic cells. 58 
Human data and information about the connection between DAMPs and PDT 
efficacy/inefficacy are missing.   
The influence of PDT on immune cells according to the available literature is summarized in 
Table 2.  
 
What is the role of dendritic cells (DCs) in the effect of PDT? 
DCs, as professional antigen presenting cells, recognize DAMPs released by dying/damaged 
tumor cells. They process antigens and migrate to regional lymph nodes, where they present 
tumor-associated antigens on their surface by MHCs. As a consequence, CD8+ cytotoxic tumor-
specific T cells (CTLs) and CD4+ T helper cells are primed, and B cells are activated, initiating 
adaptive immune response. 20, 36, 46, 59, 60  
More and more information is published regarding PDT’s effect on immune cells in mouse SCC 
models. Wang et al. 61 detected a significant increase in the number of CD1a+ DCs 24 hours 










the maturation of DCs with the upregulation of MHCII, CD80 and CD86 expression and 
proinflammatory cytokine (IFN-γ and IL-12) secretion.62 However, studies on the 
immunological effect of PDT in non-cancer models showed that PDT could have 
immunosuppressive effect on skin.36, 37 Hayami et al.36 investigated the immunological effects 
of PDT in murine contact hypersensitivity (CHS) model. The number of Langerhans cells was 
significantly decreased 1 day after PDT and the remaining ones were rounded and lacked 
dendrites. LC started to recover 5 days after PDT and reached nearly the same level 2 weeks 
after the treatment. Meanwhile the number of CD11c+ DCs was significantly increased in the 
draining lymph nodes 24 hours later, up to 5 days after PDT.36 The possible immunosuppressive 
effect of PDT is also confirmed by human data. Even in healthy human skin, the number of LCs 
was decreased significantly 24 hours after ALA-PDT.63 Nevertheless, human data are not yet 
available in the context of immunological effects of PDT on DCs in AK or cSCC. 
 
Are neutrophils involved in the effect of PDT? 
PDT induces an acute-phase response, resulting in neutrophil accumulation at the site of the 
injury. The damage of the vasculature leads to the extravasation of plasma proteins, fragmented 
extracellular matrix (ECM) and to the release of DAMPs, which recruit neutrophils to the site 
of the injury. 64, 65 Furthermore, the complement cascade is also activated, leading to membrane 
attack complex (MAC) formation with direct damage of tumor and endothelial cells and 
neutrophil chemotaxis by the presence of C3a and C5a complement degradation products. 64, 65 
Proinflammatory cytokines (IL-1β, TNF-α, IL-6, IL-8) and arachidonic acid metabolites also 
attract neutrophils. 66 Neutrophils can directly kill tumor cells by oxidative burst and ROS 
production and indirectly by the release of cytokines and chemokines that take part in the 
recruitment and activation of other immune cells; for example, active neutrophils can facilitate 
the maturation of DCs. 57, 66, 67 
Human data are also available proving that neutrophils are involved in PDT mediated immune 
response. Three hours after 5-ALA PDT of AK, marked neutrophilic infiltrate could be detected 
both in the epidermis and in the dermis, and their number decreased 3 days after PDT. 68 Rapid 
influx of neutrophils was detected in the dermis four hours after PDT in healthy human skin as 
well but their number decreased to near baseline 24 hours after PDT. 63 As LCs undergo 
phenotypic changes after PDT, it raises the question of whether neutrophils also undergo 
phenotypic and functional changes after PDT. However, there are no investigations so far to 
address this question.  
 
What cytokines are released after PDT? 
During PDT induced inflammation, various proinflammatory cytokines are released.7 The most 
prominent ones are IL-6, IL-1β and TNF-α. 66, 21 Wang et al. could detect a marked increase in 
TNF-α expression 1 week after one session of ALA-PDT in an SCC mouse model.61 In ALA-
PDT experiments performed on cultured keratinocytes, derived from photodamaged skin, 
significantly increased levels of IL-1α, IL-6 and TNF-α could be detected in the keratinocyte 
supernatant 24 hours after PDT. These cytokines not only mediate antitumor immune response 
but decrease the expression of matrix metalloproteinases (MMP-1) and increase collagen 
synthesis. In this way, these cytokines have a role in photorejuvenation as well. 69 In healthy 
human skin, the expression of TNF-α was significantly increased 24 hours after PDT, but the 
production of IL-8 and IL-1β was unchanged following PDT. 63 Regarding IL-6, its level in 










It is still not known what cytokines are elevated or decreased in AK, nor how PDT might alter 
their concentrations. Regarding the immunosuppressive effect of PDT, another interesting 
question would be, how PDT change the concentration of IL-10, TGF-β and how this influences 
treatment outcomes and recurrence rates? 
 
Is the adaptive immune system involved in the effect of PDT?  
 
The number of CD4+ and CD8+ T cells were increased at 4 hours after PDT in healthy human 
skin. 63 At 24 hours 71 and one week after ALA-PDT in an SCC mouse model, the amount of 
CDD4+ and CD8+ T cells was significantly increased.61 Long-term tumor control after PDT is 
thought to be achieved by CD8+ anti-tumor T cell response, whereas CD4+ T cells play only a 
supportive role. 72 Only one human study is available which intended to examine the number 
of Tregs in peripheral blood after MAL-PDT of AKs. The authors found that MAL-PDT did 
not influence significantly the number and even the function of Tregs in patients with multiple 
AK. 70 
Other human studies analyzing the composition of T cells in AKs or the influence of PDT on T 
cells in human AK samples are not yet available. It would be important to evaluate these 
changes to gain real information about the mechanism of action of PDT on AKs, and to possibly 
explain the occasionally observed therapeutic failure. Moreover, in terms of healing, the 
dynamics of the immune response (immune activation, immunosuppression and anti-




Conclusions and future outlook 
 
In addition to UV-induced DNA damage, UV-induced immunosuppression and inflammation 
are also essential in the development of AK and cSCC. The immune cells are well characterized 
in photodamaged skin, IEC and cSCC and partially in AK. During progression of AK to cSCC, 
the composition of immune cells is changing, giving opportunity to find prognostic tools, like 
CD4+/CD8+ ratio, although more human studies would be needed to identify an immune marker 
which would predict therapeutic efficacy. The major events induced by PDT are extensively 
studied in non-skin cancer models both in humans and animals, while the immunological effects 
of 5-ALA/MAL PDT on AK, IEC and cSCC lesions have been mainly investigated in mouse 
models. Experimental data in human are missing. It is very likely that the success of 
photodynamic therapy depends on the immune cell’s composition in actinic keratosis before 
treatment and that long-term benefit of photodynamic therapy depends on its immunological 
effects. To achieve a better lesion selection for photodynamic therapy and to develop 
appropriate therapeutic combinations, further studies evaluating the effects of PDT on 
neutrophils, DCs, cytokines and T cells in epithelial precancerous and cancerous lesions are 
needed in the future. 
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Table 1. Distribution of immune cells in human photodamaged skin, actinic keratosis, 
intraepidermal carcinoma and squamous cell carcinoma 
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